Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Clinical Trial Grant
Awarded By
Deciphera Pharmaceuticals, LLC
Start Date
October 3, 2025
End Date
September 28, 2030
Awarded By
Deciphera Pharmaceuticals, LLC
Start Date
October 3, 2025
End Date
September 28, 2030